Discover how Akero Therapeutics' EFX outshines competitors in MASH treatment, with groundbreaking results and strong ...

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic ...

American Century Companies Inc. lifted its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 55.1 ...

Corebridge Financial Inc. lowered its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 7.0% in ...

A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO), please contact Fletcher Moore by email at [email protected] or (212) 709-8245. You may be able to seek monetary damages ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Akero Therapeutics Inc (Symbol: AKRO) entered into oversold territory, hitting an RSI ...

89bio Inc . (NASDAQ:ETNB) Trades Lower in Sympathy with Akero Therapeutics (NASDAQ:AKRO) Akero -63% Following NASH DataETNB -40% ByInvesting.com • Oct 10, 2023 Akero Therapeutics Falls 48% ...